iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
iBio, Inc. (NYSEA:IBIO) announced it will release its fiscal 2022 third quarter financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing a detailed corporate update. The company specializes in next-generation biopharmaceuticals and sustainable, plant-based manufacturing through its FastPharming System. It focuses on developing treatments for cancers, fibrotic, and infectious diseases, along with offering contract development and manufacturing services.
- Company is pioneering sustainable plant-based biopharmaceutical manufacturing.
- Developing proprietary biopharmaceuticals for cancer and infectious diseases.
- None.
BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 third quarter financial results after market close on Thursday, May 12, 2022. iBio management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
The live and archived webcast may be accessed on the Company’s website at www.ibioinc.com under “News and Events” in the Investors section. The live call can be accessed by dialing (833) 672-0651 (domestic) or (929) 517-0227 (international) and referencing conference ID: 2392536.
About iBio, Inc.
iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.
Contact:
Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
FAQ
When will iBio report its third quarter financial results for fiscal 2022?
What time is the iBio conference call scheduled for?
How can I access the iBio earnings call?
What is iBio's FastPharming System?
What diseases is iBio targeting with its biopharmaceuticals?
